We performed a randomized trial of open-label ATV/r or EFV combined with abacavir/lamivudine ( ABC/@TC ) or tenofovir/emtricitabine ( TDF/FTC ) in @ human immunodeficiency virus type @-infected , treatment-naive persons enrolled between September @ and November @ at @ sites in the United States and Puerto Rico .